Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 3/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30718843 | 1.00 | ERN1 (0.41) | ERN1DYRK1ADYRK1BDYRK2PRKCI | |
| SCHEMBL435122 | 0.90 | DYRK1A (0.38) | ERN1DYRK1ADYRK1BDYRK2CLK1 | |
| SCHEMBL102388 | 0.79 | TSHR (0.35) | PKMMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2799483 | 0.76 | NPC1 (0.36) | ERN1CYP11B2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4141582 | 0.76 | CTNNB1 (0.37) | ERN1DYRK1ADYRK1BCLK1 | |
| SCHEMBL4135633 | 0.72 | ALDH1A1 (0.46) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL17828247 | 0.72 | DYRK1A (0.49) | DYRK1ADYRK1BDYRK2PRKCICYP11B2 | |
| SCHEMBL21371861 | 0.72 | DYRK1A (0.38) | ERN1DYRK1ADYRK1BDYRK2PRKCI | |
| SCHEMBL20073453 | 0.72 | DYRK1A (0.38) | ERN1DYRK1ADYRK1BDYRK2PRKCI | |
| SCHEMBL17828248 | 0.72 | DYRK1A (0.38) | ERN1DYRK1ADYRK1BDYRK2PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547658-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2022-01-25 | — | — | US | disclosed |
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| EP-3639824-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-22 | — | — | EP | disclosed |
| EP-3182973-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3182973-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-06-28 | — | — | EP | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| EP-1954697-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| WO-2007122258-A1 | TRYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122258-A1 | TRYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007115947-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007081597-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | ERN1 493/4885DYRK1A 559/4885DYRK1B 781/4885 |
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | ERN1 2182/4885DYRK1A 3749/4885DYRK1B 4011/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | ERN1 3627/4885DYRK1A 1101/4885DYRK1B 1525/4885 |
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | ERN1 1214/4885DYRK1A 4542/4885DYRK1B 4603/4885 |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GMPS, GNE, DHPS | ERN1 2858/4885DYRK1A 1931/4885DYRK1B 2179/4885 |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | ERN1 2182/4885DYRK1A 3749/4885DYRK1B 4011/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | ERN1 204/4885DYRK1A 1701/4885DYRK1B 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.